profit from every $100 of sales.
$0$100
Definitive Healthcare
$1.25-2.34% today
-54.0% in 1 year
1-year low $0.631-year high $2.87
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Definitive Healthcare sold, what it kept, and what it did with the cash.
Sales went from $223 million in 2022 to $242 million in 2025, with -$139 million of profit last year.
SalesProfit
Definitive Healthcare handed back more cash to shareholders than it generated last year.
Buybacks $49M
Free cash flow 2025$37M
Bought back its own shares$49M
Paid as dividends–
Cash vs. debt$164M vs. $173M
Definitive Healthcare vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Definitive Healthcare | No profit yet | ||
 GE HealthCare Technologies | 17.8× · Fair price | ||
 BrightSpring Health Services | 74.6× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.6× · Expensive |
AI analysis
An AI analyst reads Definitive Healthcare's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 223 | 251 | 252 | 242 | |
| 180 | 204 | 197 | 183 | |
| -36 | -31 | -10 | -21 | |
| 26 | -241 | -567 | -142 | |
| -7 | -202 | -413 | -139 | |
| -0.06 | -1.79 | -3.54 | -1.30 | |
| 80.9% | 81.1% | 78.3% | 75.9% | |
| -16.2% | -12.3% | -3.9% | -8.5% | |
| -3.2% | -80.5% | -163.8% | -57.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,123 | 1,826 | 1,089 | 735 |
| Cash | 147 | 131 | 105 | 164 |
| Total debt | 276 | 268 | 253 | 173 |
| Total liabilities | 641 | 627 | 482 | 357 |
| 949 | 861 | 444 | 281 | |
| 101 | 113 | 117 | 107 | |
| -2.0% | -20.5% | -70.1% | -34.5% | |
| -0.8% | -23.5% | -93.0% | -49.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 36 | 41 | 58 | 54 | |
| 8 | 3 | 12 | 17 | |
| 27 | 38 | 46 | 37 | |
| Dividends paid | 13 | 12 | – | – |
| 0 | 0 | 22 | 49 | |
| 36 | 49 | 38 | 29 |
Valuation
- –
- 7.5×
- –
- 0.6×
- 0.6×
- 3.6×
- –
- 27.7%
- -103.7%
- 0.0%
Profitability
- 75.9%
- -8.5%
- -57.5%
- 4.9%
- 40.9%
- -22.5%
- -67.1%
- -33.1%
- 42.6%
- 13.4%
Growth
- +2.7%
- –
- −19.2%
- –
- +2.4%
Financial health
- –
- 1.16
- 33.0%
- 13.9×
- 1.66
- 1.66
- 0.46
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 2%of 952
Bottom 15%of 883
Bottom 21%of 870
Top 2%of 985
What analysts expect
- Average price target
- $3.13
- Range
- $2.75 – $3.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.06 | 0.03 | +100.0% |
| Feb 26, 2026 | 0.06 | 0.06 | +0.0% |
| Nov 6, 2025 | 0.07 | 0.06 | +16.7% |
| Aug 7, 2025 | 0.07 | 0.05 | +40.0% |
| May 8, 2025 | 0.05 | 0.02 | +150.0% |
| Feb 27, 2025 | 0.08 | 0.07 | +14.3% |
| Nov 7, 2024 | 0.10 | 0.08 | +25.0% |
| Aug 5, 2024 | 0.09 | 0.09 | +0.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
49No pass
Benjamin Graham
59No pass
Philip Fisher
31No pass
Peter Lynch
24No pass
Joel Greenblatt
82Pass
Charlie Munger
34No pass
Terry Smith
36No pass
Questions about Definitive Healthcare
Is Definitive Healthcare a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Definitive Healthcare AI analysis
What does Definitive Healthcare do?
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. It is in Medical - Healthcare Information Services.
Does Definitive Healthcare pay a dividend?
No. Definitive Healthcare does not pay a dividend at the moment; in 2025 it returned $49.5 million to shareholders by buying back its own shares.
Is Definitive Healthcare stock halal?
No. Definitive Healthcare does not pass our halal screen: its debt is 129% of its market value, at or above the 33% limit. How we check
How has Definitive Healthcare stock done over the past year?
Down 54.0% over the past twelve months, to $1.25. It traded between $0.63 and $2.87 and is 56.4% below its high.
Who are Definitive Healthcare's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with Definitive Healthcare's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.